ICSS Proud to Announce Publication of CSN Safety Data

The Cell Surgical Network is proud to have published one of the largest peer reviewed safety data papers on the use of autologous stromal vascular fraction (SVF) to date. SVF contains adult adipose-derived mesenchymal stem cells that many scientific publications have long suggested could be used for regenerative medical purposes. The Cell Surgical Network set…

Details

Cell Expansion Study Approved

Cell Surgical Network (CSN) has partnered with American Cryostem (ACS) and has recently received approval from ICSS to study the safety of banking and expanding adipose derived stromal vascular fraction.  Both companies see this as the future of regenerative medicine: bank young healthy cells and have them available when injury or illness occur.  A practice…

Details

ICSS Approves Cell Surgical Network’s Cancer Study

ICSS has approved of Cell Surgical Network (CSN) and StemImmune Corp.’s cancer study for treating patients with advanced solid tumors.  By combining autologous adipose derived stromal vascular fraction with ACAM 2000 vaccine, CSN and StemImmune aspire to show the safety of this novel approach and eventually its effectiveness in providing medical assistance to late-stage cancer…

Details

ICSS and RTA Announce Alliance

The Regenerative Technology Alliance, a US-based 501c3 nonprofit and the ICSS have announced a global alliance to provide evaluation for the physicians who participate in the clinical studies approved by the ICSS IRB.